High dose celecoxib (C) and docetaxel (D) in patients (pts) with hormone resistant prostate cancer (HRPC). Results of an ongoing phase II trial.

被引：0
|
作者：
Kasimis, B
Cogswell, J
Hwang, S
Chang, VT
Srinivas, S
Zhong, F
Duque, L
Morales, E
Boholli, I
Blumenfrucht, M
机构：
[1] VA NJ Hlth Care Syst, E Orange, NJ USA
[2] VA New Jersey Hlth Care Syst, E Orange, NJ USA
[3] Univ Med & Dent New Jersey, VA New Jersey Hlth Care Syst, E Orange, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：428S / 428S
页数：1
相关论文
共 50 条
  • [21] High response to docetaxel (D)/carboplatin (C) based chemotherapy as salvage therapy in patients with docetaxel-resistant metastastic hormone-refractory prostate cancer (HRPC)
    Reuter, C.
    Ivanyi, P.
    Morgan, M.
    Ganser, A.
    Winkler, T.
    Fenner, M.
    Gruenwald, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] Neoadjuvant docetaxel and capecitabine in patients (Pts) with high-risk prostate cancer (PCa): Final results of a phase II trial
    Friedman, J. D.
    Vaishampayan, U.
    Wood, D.
    Wu, A.
    Bradley, D.
    Dunn, R. L.
    Montie, J.
    Sarkar, F. H.
    Shah, R.
    Hussain, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer
    Kattan, Joseph
    Bachour, Marwan
    Farhat, Fadi
    El Rassy, Elie
    Assi, Tarek
    Ghosn, Marwan
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (04) : 474 - 480
  • [24] Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer
    Joseph Kattan
    Marwan Bachour
    Fadi Farhat
    Elie El Rassy
    Tarek Assi
    Marwan Ghosn
    Investigational New Drugs, 2016, 34 : 474 - 480
  • [25] Results of a phase II study of picoplatin with docetaxel and prednisone in chemotherapy-naive patients with metastatic hormone refractory prostate cancer (HRPC)
    DeJager, R.
    Roman, L.
    Lopatkin, N.
    Karlov, P.
    Breitz, H. B.
    Earhart, R.
    EJC SUPPLEMENTS, 2008, 6 (12): : 67 - 67
  • [26] A phase II clinical study of high-dose calcitriol plus docetaxel and zoledronic acid in hormone-refractory prostate cancer (HRPC)
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 94 - 94
  • [27] Docetaxel (D) plus prednisone (P) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line chemotherapy in metastatic hormone refractory prostate cancer (HRPC): Phase II clinical trial with pharmacodynamic evaluation
    Fontana, A.
    Bocci, G.
    D'Arcangelo, M.
    Galli, L.
    Galli, C.
    Bursi, S.
    Landi, L.
    Antonuzzo, A.
    Del Tacca, M.
    Falcone, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] Phase II clinical trial of metronomic cyclophosphamide (CTX) plus celecoxib (C) and dexamethasone (DEX) in advanced hormone refractory prostate cancer (HRPC): preliminary clinical and pharmacodynamic results
    Fontana, A.
    Bocci, G.
    Galli, L.
    Fontana, E.
    Galli, C.
    Landi, L.
    Fioravanti, A.
    Di Marsico, R.
    Del Tacca, M.
    Facone, A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 288 - 288
  • [29] Combination of a polyamine-free oral nutritional supplement (ONS) with docetaxel in castrate-resistant prostate cancer (CRPC) patients (pts): A phase II trial.
    Cipolla, Bernard G.
    Artignan, Xavier
    Miglianico, Laurent
    Bligny, Dominique
    Abraham, Christine
    Moulinoux, Jacques Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [30] Phase I study of picoplatin and docetaxel (D) with prednisone (P) in patients (pts) with chemotherapy-naive metastatic hormone refractory prostate cancer (HRPC)
    Roman, L.
    Karlov, P.
    Kaprin, A.
    Gladkov, O.
    Breitz, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345